Reactivation of hepatitis B virus (HBV) infection in adult T-cell leukemia–lymphoma patients with resolved HBV infection following systemic chemotherapy

International Journal of Hematology

Volumn 101, Issue 4, 2015, Pages 398-404

  Totani, Haruhito ^a   Kusumoto, Shigeru ^a   Ishida, Takashi ^a   Masuda, Arisa ^a   Yoshida, Takashi ^a   Ito, Asahi ^a   Ri, Masaki ^a   Komatsu, Hirokazu ^a   Murakami, Shuko ^a   Mizokami, Masashi ^b   Ueda, Ryuzo ^c   Niimi, Akio ^a   Inagaki, Hiroshi ^a   Tanaka, Yasuhito ^a   Iida, Shinsuke ^a  

^a NAGOYA CITY UNIVERSITY GRADUATE SCHOOL OF MEDICAL SCIENCES   (Japan)

^b NATIONAL CENTER FOR GLOBAL HEALTH AND MEDICINE   (Japan)

^c AICHI MEDICAL UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

ATL; CCR4; HBV; Mogamulizumab; Reactivation

Indexed keywords

ANTIVIRUS AGENT; MOGAMULIZUMAB; MONOCLONAL ANTIBODY; VIRUS DNA;

ADULT; AGED; COMPLICATION; DRUG EFFECTS; FEMALE; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; ISOLATION AND PURIFICATION; LEUKEMIA-LYMPHOMA, ADULT T-CELL; MALE; MIDDLE AGED; RETROSPECTIVE STUDY; VIROLOGY;

ADULT; AGED; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTIVIRAL AGENTS; DNA, VIRAL; FEMALE; HEPATITIS B; HEPATITIS B VIRUS; HUMANS; LEUKEMIA-LYMPHOMA, ADULT T-CELL; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES;

EID: 84939937110     PISSN: 09255710     EISSN: 18653774     Source Type: Journal    
DOI: 10.1007/s12185-015-1750-z     Document Type: Article

References (21)

1. Lok AS, Liang RH, Chiu EK, Wong KL, Chan TK, Todd D. Reactivation of hepatitis B virus replication in patients receiving cytotoxic therapy. Report of a prospective study. Gastroenterology. 1991;100(1):182–8.
2. Hui CK, Cheung WW, Zhang HY, Au WY, Yueng YH, Leung AY, et al. Kinetics and risk of de novo hepatitis B infection in HBsAg-negative patients undergoing cytotoxic chemotherapy. Gastroenterology. 2006;131(1):59–68.
3. Yeo W, Chan TC, Leung NW, Lam WY, Mo FK, Chu MT, et al. Hepatitis B virus reactivation in lymphoma patients with prior resolved hepatitis B undergoing anticancer therapy with or without rituximab. J Clin Oncol. 2009;27(4):605–11 (Epub 2008/12/17).
4. Kusumoto S, Tanaka Y, Mizokami M, Ueda R. Reactivation of hepatitis B virus following systemic chemotherapy for malignant lymphoma. Int J Hematol. 2009;90(1):13–23 (Epub 2009/06/23).
5. Kusumoto S, Tanaka Y, Ueda R, Mizokami M. Reactivation of hepatitis B virus following rituximab-plus-steroid combination chemotherapy. J Gastroenterol. 2011;46(1):9–16 (Epub 2010/10/07).
6. Mitka M. FDA: increased HBV reactivation risk with ofatumumab or rituximab. JAMA. 2013;310(16):1664.
7. Ishida T, Utsunomiya A, Iida S, Inagaki H, Takatsuka Y, Kusumoto S, et al. Clinical significance of CCR4 expression in adult T-cell leukemia/lymphoma: its close association with skin involvement and unfavorable outcome. Clin Cancer Res. 2003;9(10 Pt 1):3625–34.
8. Ishii T, Ishida T, Utsunomiya A, Inagaki A, Yano H, Komatsu H, et al. Defucosylated humanized anti-CCR4 monoclonal antibody KW-0761 as a novel immunotherapeutic agent for adult T-cell leukemia/lymphoma. Clin Cancer Res. 2010;16(5):1520–31.
9. Yamamoto K, Utsunomiya A, Tobinai K, Tsukasaki K, Uike N, Uozumi K, et al. Phase I study of KW-0761, a defucosylated humanized anti-CCR4 antibody, in relapsed patients with adult T-cell leukemia–lymphoma and peripheral T-cell lymphoma. J Clin Oncol. 2010;28(9):1591–8.
10. Ishida T, Ueda R. Antibody therapy for Adult T-cell leukemia–lymphoma. Int J Hematol. 2011;94(5):443–52.
11. Ishida T, Joh T, Uike N, Yamamoto K, Utsunomiya A, Yoshida S, et al. Defucosylated anti-CCR4 monoclonal antibody (KW-0761) for relapsed adult T-cell leukemia–lymphoma: a multicenter phase II study. J Clin Oncol. 2012;30(8):837–42.
12. Motohashi K, Suzuki T, Kishimoto K, Numata A, Nakajima Y, Tachibana T, et al. Successful treatment of a patient with adult T cell leukemia/lymphoma using anti-CC chemokine receptor 4 monoclonal antibody mogamulizumab followed by allogeneic hematopoietic stem cell transplantation. Int J Hematol. 2013;98(2):258–60.
13. Nakano N, Kusumoto S, Tanaka Y, Ishida T, Takeuchi S, Takatsuka Y, et al. Reactivation of hepatitis B virus in a patient with adult T-cell leukemia–lymphoma receiving the anti-CC chemokine receptor 4 antibody mogamulizumab. Hepatol Res. 2014;44(3):354–7.
14. Shin IT, Tanaka Y, Tateno Y, Mizokami M. Development and public release of a comprehensive hepatitis virus database. Hepatol Res. 2008;38(3):234–43.
15. Hsu C, Tsou HH, Lin SJ, Wang MC, Yao M, Hwang WL, et al. Chemotherapy-induced hepatitis B reactivation in lymphoma patients with resolved HBV infection: a prospective study. Hepatology. 2014;59(6):2092–100.
16. Kusumoto S, Tanaka Y, Suzuki R, Watanabe T, Nakata M, Takasaki H, et al. Prospective nationwide observational study of hepatitis B virus (HBV) DNA monitoring and preemptive antiviral therapy for HBV reactivation in patients with B-cell non-Hodgkin lymphoma following rituximab containing chemotherapy: results of interim analysis. Blood. 2012; 120(21):abstract 2641.
17. Tsukasaki K, Utsunomiya A, Fukuda H, Shibata T, Fukushima T, Takatsuka Y, et al. VCAP-AMP-VECP compared with biweekly CHOP for adult T-cell leukemia–lymphoma: Japan Clinical Oncology Group Study JCOG9801. J Clin Oncol. 2007;25(34):5458–64.
18. Jo T, Ishida T, Takemoto S, Suzushima H, Uozumi K, Yamamoto K, et al. Randomized phase II study of mogamulizumab (KW-0761) plus VCAP-AMP-VECP (mLSG15) versus mLSG15 alone for newly diagnosed aggressive adult T-cell leukemia–lymphoma (ATL). J Clin Oncol 2013; 31: (suppl; abstr 8506).
19. Ishida T, Ueda R. Immunopathogenesis of lymphoma: focus on CCR4. Cancer Sci. 2011;102(1):44–50.
20. Oketani M, Ido A, Uto H, Tsubouchi H. Prevention of hepatitis B virus reactivation in patients receiving immunosuppressive therapy or chemotherapy. Hepatol Res. 2012;42(7):627–36 Epub 2012/06/13.
21. EASL clinical practice guidelines. Management of chronic hepatitis B virus infection. J Hepatol. 2012;57(1):167–85 Epub 2012/03/23.